Visualizing
the distribution of small-molecule drugs in living
cells is an important strategy for developing specific, effective,
and minimally toxic drugs. As an alternative to fluorescence imaging
using bulky fluorophores or cell fixation, stimulated Raman scattering
(SRS) imaging combined with bisarylbutadiyne (BADY) tagging enables
the observation of small molecules closer to their native intracellular
state. However, there is evidence that the physicochemical properties
of BADY-tagged analogues of small-molecule drugs differ significantly
from those of their parent drugs, potentially affecting their intracellular
distribution. Herein, we developed a modified BADY to reduce deviations
in physicochemical properties (in particular, lipophilicity and membrane
permeability) between tagged and parent drugs, while maintaining high
Raman activity in live-cell SRS imaging. We highlight the practical
application of this approach by revealing the nuclear distribution
of a modified BADY-tagged analogue of JQ1, a bromodomain and extra-terminal
motif inhibitor with applications in targeted cancer therapy, in living
HeLa cells. The modified BADY, methoxypyridazyl pyrimidyl butadiyne
(MPDY), revealed intranuclear JQ1, while BADY-tagged JQ1 did not show
a clear nuclear signal. We anticipate that the present approach combining
MPDY tagging with live-cell SRS imaging provides important insight
into the behavior of intracellular drugs and represents a promising
avenue for improving drug development.